Journal article
Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era
Blood cancer journal (New York), Vol.11(7), pp.133-133
07/17/2021
DOI: 10.1038/s41408-021-00525-0
PMCID: PMC8286048
PMID: 34274939
Abstract
Immediate treatment for asymptomatic, low-tumor burden follicular lymphoma (FL) has not shown an overall survival benefit over "watch and wait" (W/W) strategy. We estimated incidence of treatment initiation at specific time points and assessed its association with the presence of any criteria such as GELF, BNLI, GITMO at diagnosis. FL patients managed by W/W strategy were identified from the Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic Lymphoma SPORE between 2002 and 2015. Cumulative incidence estimates of treatment initiation were calculated using transformation (as the first event) and death as competing risks. 401 FL patients were identified on W/W strategy. At a median follow-up of 8 years, 256 (64%) initiated treatment. For patients on the W/W strategy for 5 years, the likelihood of treatment initiation in the next 5 years was 12% compared to 43% at diagnosis unlike transformation rates which remained steady. Patients with any of popular treatment criteria at diagnosis did not have increased therapy initiation rates (44% vs. 42%) during the first 5 years or lymphoma-related death rates at 10 years (6% vs. 7%). Identifying biological differences in patients with early vs. late or no progression is a critical next step in understanding outcomes in W/W patients.
Details
- Title: Subtitle
- Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era
- Creators
- Arushi Khurana - Mayo ClinicRaphael Mwangi - Mayo Clinic in FloridaStephen M Ansell - Mayo ClinicThomas M Habermann - Mayo ClinicJames R Cerhan - Mayo Clinic in FloridaChristopher Strouse - University of IowaBrian K Link - University of IowaYucai Wang - Mayo Clinic in FloridaRebecca L King - Mayo Clinic in FloridaWilliam R Macon - Mayo ClinicJ C Villasboas - Mayo Clinic in FloridaThomas E Witzig - Mayo Clinic in FloridaMatthew J Maurer - Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USAGrzegorz S Nowakowski - Mayo Clinic
- Resource Type
- Journal article
- Publication Details
- Blood cancer journal (New York), Vol.11(7), pp.133-133
- DOI
- 10.1038/s41408-021-00525-0
- PMID
- 34274939
- PMCID
- PMC8286048
- NLM abbreviation
- Blood Cancer J
- ISSN
- 2044-5385
- eISSN
- 2044-5385
- Grant note
- U01 CA195568 / NCI NIH HHS T32 HL007344 / NHLBI NIH HHS P30 CA086862 / NCI NIH HHS P50 CA097274 / NCI NIH HHS
- Language
- English
- Date published
- 07/17/2021
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Internal Medicine
- Record Identifier
- 9984360040602771
Metrics
13 Record Views